A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT05361174
Phase
PHASE1 / PHASE2
Sponsor
Iovance Biotherapeutics, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • IOV-4001
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Miami, Florida, United States|25.77427,-80.19366
  • Orlando, Florida, United States|28.53834,-81.37924
  • Tampa, Florida, United States|27.94752,-82.45843
  • Westwood, Kansas, United States|39.04056,-94.6169

Key Eligibility Criteria

  • Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma or Stage III or IV NSCLC.
  • Participants who have received the following previous therapy:
  • Cohort 1 (Melanoma): Participants who have progressed within 12 weeks of last dose of anti-PD-1/PD-L1 blocking antibody and received BRAF/MEK inhib…
  • Cohort 2 (NSCLC): Participants who should have received no more than 3 prior lines of therapy and:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →